Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada.
Transl Res. 2010 May;155(5):220-7. doi: 10.1016/j.trsl.2009.12.005. Epub 2010 Jan 19.
Expense, high drug dose, and low compliance to strict dietary therapies are current issues surrounding modern drug- and diet-based lipid-lowering approaches. Furthermore, variable patient outcomes and suboptimal response to both drug and diet therapies are increasingly evident. Therefore, the question arises as to whether more emphasis should be placed on combination diet/drug therapies to reduce cholesterol levels in patients who respond suboptimally to diet and drug monotherapies. Although considerable research has explored multidrug combination therapies, combination drug/diet therapies receive less attention. However, combined drug/diet approaches may reduce the number of drug prescriptions, the progressive increase in "optimal" drug dosage, and costs associated with pharmaceutical disease management. Future research priorities in drug/diet therapeutic approaches should not only emphasize the discovery of novel combinations but also should address potential safety issues prior to wide-scale acceptance in clinical practice. Accordingly, this review will assess current limitations associated with both drug and diet lipid-lowering therapies and explore the potential of combination drug/diet therapies in the treatment of dyslipidemia.
费用高、药物剂量大、严格饮食疗法的依从性低是目前药物和饮食降脂方法所面临的问题。此外，患者的治疗结果存在差异，药物和饮食治疗的反应也不理想。因此，人们不禁要问，对于那些对饮食和药物单一疗法反应不佳的患者，是否应该更加重视联合饮食/药物疗法来降低胆固醇水平。尽管有大量的研究探索了多药物联合治疗，但联合药物/饮食治疗却没有得到足够的重视。然而，联合药物/饮食的方法可以减少药物处方的数量、逐渐增加“最佳”药物剂量以及与药物治疗相关的成本。药物/饮食治疗方法的未来研究重点不仅应强调新的联合用药，还应在广泛应用于临床实践之前解决潜在的安全问题。因此，本综述将评估目前药物和饮食降脂治疗的局限性，并探讨联合药物/饮食治疗在治疗血脂异常方面的潜力。
